Taranabant, specifically the (1R,2R) stereoisomer, was primarily investigated as a potent and selective cannabinoid-1 (CB1) receptor inverse agonist. Its primary application was in the field of weight management and obesity treatment. By blocking the CB1 receptor, it aimed to reduce appetite and food intake, thereby promoting weight loss in individuals with obesity. Clinical trials explored its efficacy in helping patients achieve significant weight reduction when combined with lifestyle changes. However, development was discontinued due to adverse psychiatric side effects, including anxiety and depression, which outweighed its potential benefits. Despite its discontinuation, research on Taranabant contributed to a better understanding of the endocannabinoid system and its role in metabolism and appetite regulation.